| Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 16227141 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Our previous studies suggest that the increase in heart rate from rest to peak exercise is reduced in patients with chronic heart failure (CHF) and this is associated with increased oxidative stress, as determined by malondialdehyde (MDA) plasma levels. AIM: To investigate the effects of carvedilol on the heart rate response to exercise and oxidative stress in patients with CHF. METHODS AND RESULTS: Thirty stable NYHA classes II-III CHF patients received carvedilol therapy for 6 months, at a mean maintenance dose of 25 mg (range 6.25-50 mg/day). After treatment, the patients showed a significant improvement in their functional NYHA class (p=0.013), increased left ventricular ejection fraction (LVEF) (24+/-1.4% to 31+/-2.3%, p=0.003) and 6-min walk distance (499+/-18 to 534+/-18 m, p=0.03), without changes in the peak VO2. At baseline, norepinephrine (NE) plasma levels increased with exercise (510+/-51 to 2513+/-230 pg/mL, p<0.001), and these levels were not affected by carvedilol. Chronotropic responsiveness index (increase in heart rate divided by the increase in NE from rest to peak exercise) was not changed by carvedilol (0.049+/-0.001 to 0.042+/-0.001, p=0.6). MDA levels of CHF patients decreased after treatment with carvedilol (2.4+/-0.2 to 1.1+/-0.2 microM, p<0.001), without changes in antioxidant enzyme activities. CONCLUSIONS: Carvedilol treatment in patients with CHF results in reduced oxidative stress without restoration of the chronotropic responsiveness index. |
| | |
Authors:
|
Pablo Castro; José Luis Vukasovic; Mario Chiong; Guillermo Díaz-Araya; Hernán Alcaino; Miguel Copaja; Rodrigo Valenzuela; Douglas Greig; Osvaldo Pérez; Ramón Corbalan; Sergio Lavandero |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of heart failure Volume: 7 ISSN: 1388-9842 ISO Abbreviation: Eur. J. Heart Fail. Publication Date: 2005 Oct |
Date Detail:
|
Created Date: 2005-10-17 Completed Date: 2006-01-23 Revised Date: 2011-06-08 |
Medline Journal Info:
|
Nlm Unique ID: 100887595 Medline TA: Eur J Heart Fail Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1033-9 Citation Subset: IM |
Affiliation:
|
Cardiovascular Diseases, Universidad Católica de Chile, Santiago, Chile. pcastro@med.puc.cl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Aged Carbazoles / therapeutic use* Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Glutathione Peroxidase / analysis, metabolism Heart Failure / drug therapy*, enzymology*, radionuclide imaging Heart Function Tests Heart Rate / drug effects* Humans Linear Models Male Malondialdehyde / analysis, metabolism Middle Aged Norepinephrine / metabolism Oxidative Stress / drug effects*, physiology Probability Propanolamines / therapeutic use* Prospective Studies Radionuclide Ventriculography / drug effects Severity of Illness Index Stroke Volume / drug effects Superoxide Dismutase / analysis, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 51-41-2/Norepinephrine; 542-78-9/Malondialdehyde; 72956-09-3/carvedilol; EC 1.11.1.9/Glutathione Peroxidase; EC 1.15.1.1/Superoxide Dismutase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Alveolar-capillary membrane conductance is the best pulmonary function correlate of exercise ventila...
Next Document: Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy fo...